{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Antithrombotic Therapy After TAVI","description":" As TAVI expands to younger and healthier patients, valve durability has become an increasingly important consideration. However, the optimal antithrombotic strategy to support long-term valve function remains unclear. This trial compared antiplatelet monotherapy with NOAC monotherapy to help address this unmet need.&amp;nbsp;   In this episode, Deepak L. Bhatt MD, MPH, MBA, FACC and \u00d8yvind H. Lie, MD, PhD, MSc examine the results of \u201cACASA-TAVI: Antithrombotic therapy after TAVI\u201d.&amp;nbsp;  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42992448\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/206539978"}